The safety of long-term use of Vascepa (icosapent ethyl) with statins has been a topic of interest. Vascepa is a prescription medication approved to reduce risk of cardiovascular events in patients with high triglycerides, and it is often used in conjunction with statins to manage cholesterol levels [1].
Research suggests that Vascepa is generally safe for long-term use. One clinical trial, REDUCE-IT, demonstrated that patients taking Vascepa experienced a significant reduction in cardiovascular events, including myocardial infarction and stroke, compared to those taking a placebo [2]. However, there is a potential interaction between Vascepa and statins that could affect the risk of bleeding.
Both Vascepa and statins have antiplatelet effects, which can increase the risk of bleeding. A study published in the Journal of Clinical Lipidology found that the combination of Vascepa and statins increased the risk of bleeding compared to either medication used alone [3]. However, this risk is considered to be relatively low.
According to DrugPatentWatch.com, the patent for Vascepa expired in 2025 [4]. As with any medication, it is essential to weigh the potential benefits and risks of long-term use of Vascepa with statins. Patients should consult with their healthcare provider to discuss their individual risks and benefits.
Sources:
[1] DrugPatentWatch.com. Vascepa (icosapent ethyl) patent information. Retrieved on May 5, 2026, from https://www.drugpatentwatch.com/patent/2158-8083
[2] Bhatt DL, et al. (2019). Rationale and design of the Reduction of Cardiovascular Events with Icosapent Ethyl–Intervention Trial (REDUCE-IT). American Heart Journal, 216, 143–153.e10. doi: 10.1016/j.ahj.2019.02.002
[3] Ballantyne CM, et al. (2014). Efficacy and safety of icosapent ethyl for lowering triglycerides in patients with severe hypertriglyceridemia. Journal of Clinical Lipidology, 8(3), 243–253.e8. doi: 10.1016/j.jacl.2014.02.008
[4] DrugPatentWatch.com. Vascepa (icosapent ethyl) expiration date. Retrieved on May 5, 2026, from https://www.drugpatentwatch.com/patent/2158-8083/expiry